Margaret Gulley

Dr. Margaret Gulley

Department of Pathology, University of North Carolina, 160 Medical Dr, Brinkhous-Bullitt Building, Chapel Hill, NC 27599, USA
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2008 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
MGMargaret Gulley
Margaret Gulley
WTWeihua Tang
Weihua Tang

1 April 2010 in Clinical Microbiology Reviews
Verified
Journal Article
Open access
PDF file
MGMargaret Gulley
Margaret Gulley
WTWeihua Tang
Weihua Tang
SUMMARY: Epstein-Barr virus (EBV) DNA measurement is being incorporated into routine medical practice to help diagnose, monitor, and predict posttransplant lymphoproliferative disorder (PTLD) in immunocompromised graft recipients. PTLD is an aggressive neoplasm that almost always harbors EBV DNA within the neoplastic lymphocytes, and it is often fatal if not recognized and treated promptly. Validated protocols, commercial reagents, and automated instruments facilitate implementation of EBV load assays by real-time PCR. When applied to either whole blood or plasma, EBV DNA levels reflect clinical status with respect to EBV-related neoplasia. While many healthy transplant recipients have low viral loads, high EBV loads are strongly associated with current or impending PTLD. Complementary laboratory assays as well as histopathologic examination of lesional tissue help in interpreting modest elevations in viral load. Circulating EBV levels in serial samples reflect changes in tumor burden and represent an effective, noninvasive tool for monitoring the efficacy of therapy. In high-risk patients, serial testing permits early clinical intervention to prevent progression toward frank PTLD. Restoring T cell immunity against EBV is a major strategy for overcoming PTLD, and novel EBV-directed therapies are being explored to thwart virus-driven neoplasia.

1 May 2009 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Open access
PDF file
LJLawrence Jennings
Lawrence Jennings
VDVivianna M. Van Deerlin
Vivianna M. Van Deerlin
MGMargaret Gulley
Margaret Gulley
Context. —The use of DNA- and RNA-based tests continues to grow for applications as varied as inherited disease, infectious disease, cancer, identity testing, human leukocyte antigen typing, and pharmacogenetics. Progress is driven in part by the huge growth in knowledge about the molecular basis of disease coupled with advancements in technologic capabilities. In addition to requirements for clinical utility, every molecular test also may have limitations that must be carefully considered before clinical implementation. Analytic and clinical performance characteristics as well as test limitations are established and documented through the process of test validation. Objective. —To describe the established principles of test validation, along with relevant regulations in the United States, in order to provide a rational approach to introducing molecular tests into the clinical laboratory. Data Sources. —PubMed review of published literature, published guidelines, and online information from national and international professional organizations. Conclusions. —These resources and recommendations provide a framework for validating clinical tests.

1 November 2004 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
JRJulie L. Ryan
Julie L. Ryan
HFHongxin Fan
Hongxin Fan
SGSally L. Glaser
Sally L. Glaser
SSSteven A. Schichman
Steven A. Schichman
NRNancy Raab-Traub
Nancy Raab-Traub
MGMargaret Gulley
Margaret Gulley

13 March 2012 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
JRJulie L. Ryan
Julie L. Ryan
YSYou-Jun Shen
You-Jun Shen
DMDouglas R. Morgan
Douglas R. Morgan
LTLeigh B. Thorne
Leigh B. Thorne
SKShannon C. Kenney
Shannon C. Kenney
MGMargaret Gulley
Margaret Gulley

30 June 2011 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
FEFathi Elloumi
Fathi Elloumi
ZHZhiyuan Hu
Zhiyuan Hu
YLYan Li
Yan Li
JPJoel S Parker
Joel S Parker
MGMargaret Gulley
Margaret Gulley
MTMelissa A. Troester
Melissa A. Troester
Background: Genomic tests are available to predict breast cancer recurrence and to guide clinical decision making. These predictors provide recurrence risk scores along with a measure of uncertainty, usually a confidence interval. The confidence interval conveys random error and not systematic bias. Standard tumor sampling methods make this problematic, as it is common to have a substantial proportion (typically 30-50%) of a tumor sample comprised of histologically benign tissue. This "normal" tissue could represent a source of non-random error or systematic bias in genomic classification. Methods: To assess the performance characteristics of genomic classification to systematic error from normal contamination, we collected 55 tumor samples and paired tumor-adjacent normal tissue. Using genomic signatures from the tumor and paired normal, we evaluated how increasing normal contamination altered recurrence risk scores for various genomic predictors. Results: Simulations of normal tissue contamination caused misclassification of tumors in all predictors evaluated, but different breast cancer predictors showed different types of vulnerability to normal tissue bias. While two predictors had unpredictable direction of bias (either higher or lower risk of relapse resulted from normal contamination), one signature showed predictable direction of normal tissue effects. Due to this predictable direction of effect, this signature (the PAM50) was adjusted for normal tissue contamination and these corrections improved sensitivity and negative predictive value. For all three assays quality control standards and/or appropriate bias adjustment strategies can be used to improve assay reliability. Conclusions: Normal tissue sampled concurrently with tumor is an important source of bias in breast genomic predictors. All genomic predictors show some sensitivity to normal tissue contamination and ideal strategies for mitigating this bias vary depending upon the particular genes and computational methods used in the predictor.